We are live on
!
Find out more
NRS
Neville Rodie & Shaw Portfolio holdings
AUM
$1.55B
1-Year Est. Return
46.95%
This Fund
S&P 500
This Quarter
Est. Return
+11.9%
1 Year Est. Return
+46.95%
3 Year Est. Return
+114.59%
5 Year Est. Return
+149.24%
10 Year Est. Return
+497.97%
AUM
$1.41B
AUM Growth
+$125M
(+9.7%)
Cap. Flow
-$6.29M
Cap. Flow
% of AUM
-0.45%
Top 10 Holdings %
Top 10 Hldgs %
35.33%
Holding
276
New
13
Increased
51
Reduced
96
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cleveland-Cliffs
CLF
|
+$3.71M |
| 2 |
ExxonMobil
XOM
|
+$2.57M |
| 3 |
Palo Alto Networks
PANW
|
+$1.41M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$1.2M |
| 5 |
United Rentals
URI
|
+$909K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$3.95M |
| 2 |
Verizon
VZ
|
+$2.07M |
| 3 |
NextEra Energy
NEE
|
+$1.38M |
| 4 |
Intel
INTC
|
+$1.28M |
| 5 |
IBM
IBM
|
+$1.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.1% |
| 2 | Healthcare | 19.24% |
| 3 | Financials | 13.15% |
| 4 | Industrials | 11.27% |
| 5 | Communication Services | 8.39% |
Similar funds
PMFA
NPA
IWA
ZBNA
BGCP
MSA
VWM
CET
Neville Rodie & Shaw's Q4 2021 Portfolio in Review
As of Q4 2021, Neville Rodie & Shaw held 276 positions worth $1.41B, up 9.7% from $1.29B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Neville Rodie & Shaw's Q4 2021 filing shows 13 new, 51 increased, 96 reduced and 8 closed positions. Its largest new stake was Cleveland-Cliffs: 172,300 shares worth $3.75M. The largest sale was Acceleron Pharma, an estimated $3.95M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.
- Neville Rodie & Shaw's largest Q4 2021 buy was Cleveland-Cliffs: 172,300 shares worth $3.75M.
- Neville Rodie & Shaw added most to ExxonMobil in Q4 2021, an estimated $2.57M increase.
- Neville Rodie & Shaw's biggest Q4 2021 reduction was Verizon, cutting an estimated $2.07M.
- Neville Rodie & Shaw fully exited Acceleron Pharma in Q4 2021, selling an estimated $3.95M.
- Neville Rodie & Shaw's ten largest holdings make up 35% of its $1.41B portfolio in Q4 2021.
- Neville Rodie & Shaw opened 13 new positions and closed 8 in Q4 2021.
- Neville Rodie & Shaw's portfolio value rose 9.7% quarter-over-quarter to $1.41B.
Based on Neville Rodie & Shaw's 13F filing for Q4 2021, filed 5 Jan 2022.